Ovagen
Hepatic / GIAlso known as: Glu-Asp-Leu, EDL
Mechanism
A tripeptide bioregulator for liver and GI tract health. It restores hepatocyte function and modulates gene expression in liver cells. Studied in chronic hepatitis models where it showed improvements in liver enzyme levels and tissue regeneration.
Technical detail
Synthetic tripeptide (Glu-Asp-Leu) targeting hepatic and gastrointestinal tissues. Proposed mechanism: sequence-specific binding to regulatory DNA regions in hepatocytes, modulating expression of genes involved in detoxification (CYP450 family), albumin synthesis, and hepatocyte proliferation. In CCl4-induced hepatitis models, Ovagen treatment normalized ALT/AST levels, improved histological markers, and restored hepatic protein synthesis. Overlaps functionally with Livagen (tetrapeptide) but as a shorter tripeptide may have different tissue penetration kinetics. Published in Russian gerontology literature (Khavinson et al.).
Effects
**Gastrointestinal System (Tier 2 — Animal + In Vitro):** Ovagen is a tripeptide bioregulator (Lys-Glu-Asp) from the Khavinson system, targeting liver and gastrointestinal tract tissue. It promotes normalization of GI mucosal integrity, supporting epithelial cell proliferation and tight junction protein expression. Animal models show improved mucosal healing in gastritis and enteritis models. **Hepatic System (Tier 2 — Animal):** Overlapping hepatoprotective activity with Livagen. Promotes hepatocyte protein synthesis and supports detoxification enzyme expression. The Khavinson system considers Ovagen as having a broader hepato-GI profile compared to Livagen's more liver-specific focus. **Chromatin & Gene Expression (Tier 2 — In Vitro):** Like other Khavinson bioregulators, Ovagen modulates chromatin condensation state in target tissue nuclei, increasing transcriptional activity of genes related to GI mucosal maintenance and liver function. **Immune System — Gut-Associated (Tier 3 — Preclinical):** May support gut-associated lymphoid tissue (GALT) function and normalize mucosal immune responses. Theoretical benefit for conditions involving GI immune dysregulation.
Practitioner Guide
**CONTEXT:** • Ovagen is the GI/liver bioregulator in the Khavinson system. Often used alongside Livagen (liver-specific) for comprehensive hepato-GI support. • Same sourcing and availability considerations as Livagen — primarily European/Russian supply chain. **DOSING (Based on Khavinson Protocols):** • Oral capsule: 10 mg daily for 10–30 days. • Cycles: 10-day course, repeated every 3–6 months. Can be taken concurrently with Livagen. • Some practitioners use 20-day courses for active GI complaints (gastritis, IBS-like symptoms). **CLINICAL PEARLS:** • In the Khavinson system, Ovagen is considered the first-line bioregulator for GI mucosal issues and is often combined with Livagen for dual hepato-GI support. • Western practitioners may find it useful as part of a comprehensive gut health protocol alongside better-studied interventions (BPC-157 for gut healing, probiotics, dietary modification). • Minimal reported adverse effects. Oral administration is straightforward. • Not a replacement for standard GI workup and treatment for serious GI pathology.
Research Summary
**Tier 1 (Human Clinical Evidence):** • Very limited Western data. Russian clinical reports describe improvements in gastritis symptoms, liver function markers, and GI mucosal integrity in small patient series. Published primarily in Russian-language biogerontology journals. **Tier 2 (Strong Preclinical + Mechanistic):** • In vitro studies demonstrate chromatin remodeling effects in GI epithelial cells and hepatocytes. • Animal models of gastric and intestinal mucosal damage show accelerated healing with Ovagen treatment. • Consistent with the broader Khavinson bioregulator mechanism of tissue-specific gene expression modulation via short peptide-DNA interactions. **Tier 3 (Emerging / Theoretical):** • Same limitations as Livagen: the tissue-specific DNA interaction mechanism for a tripeptide is not fully validated by Western research standards. • The dual hepato-GI targeting claim requires more rigorous investigation.